Oncolytics Biotech Inc. — Company profile
Healthcare · Biotechnology · Canada
Last price 0.4254 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 54.24M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Details
| Name | Oncolytics Biotech Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 29 |
| Founded | 1998 |
| Ipo Date | 1999-11-08 |
| Ceo | Jared Kelly |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US68237V1035 |
| Cusip | 68237V103 |
| Cik | 0001129928 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| John McAdory | Chief Operating Officer |
| Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Jon Patton | Director of Investor Relations and Communication |
| Yujun Wu | Vice President and Head of Biostatistics |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Contact
| Address | 4350 Executive Drive, Suite 325, San Diego, California 92121, United States |
| Phone | 403 670 7377 |
| Website | https://oncolyticsbiotech.com |